摘要
As a key immune cytokine, C-X-C motif chemokine ligand 13 (CXCL13) has been reported to play critical roles in immune control of hepatitis B virus (HBV) infection. We aimed to screen single-nucleotide polymorphisms (SNPs) of CXCL13 for predicting response to pegylated interferon-alpha (PegIFNa) therapy of chronic hepatitis B (CHB) patients. Two independent cohorts with a total of 945 (Cohort 1, n = 238; Cohort 2, n = 707) hepatitis B e antigen (HBeAg)-positive CHB patients treated with PegIFNa were enrolled in this retrospective cohort study. Eight candidate SNPs were selected through gene-wide SNP mining within or flanking CXCL13. A polygenic score (PGS) was utilized to assess the cumulative effects of multiple SNPs. The associations of candidate SNPs and PGS with combined response (CR, defined as the combination of HBeAg seroconversion and HBV DNA level <3.3log(10) IU/mL) and hepatitis B surface antigen (HBsAg) level were evaluated. Among the eight candidate SNPs, rs76084459 which is located at upstream of CXCL13 was significantly associated with both CR (p = 0.002) and HBsAg level (p = 0.015). A PGS integrating CXCL13_rs76084459 and five other SNPs, which were previously identified as predictors of PegIFNa treatment response, was further strongly correlated with CR (p = 1.759 x 10(-10)) and HBsAg level (p = 0.004). This study demonstrated that CXCL13_rs76084459 can predict response to PegIFNa treatment of HBeAg-positive CHB patients. A PGS composed of six SNPs including CXCL13_rs76084459 predicts PegIFNa treatment response better.
学科与关键词
- An intronic genetic variant of ZHX2 predicts response to pegylated interferon α therapy in HBeAg-positive chronic hepatitis B patientsHou, Jia; Dong, Chao; Chen, Jiaxuan; Chen, Haitao; Na, Rong; Zhou, Bin; Hou, Jinlin*; Jiang, De-Ke*Antiviral Research, 2023, 220: 105741.
- CD55 Variant Associated with Pegylated-interferon α Therapy Response in HBeAg-positive Chronic Hepatitis B PatientsChen, Jiaxuan; Lou, Shuang; Chen, Haitao; Zhou, Bin; Sun, Jian; Hou, Jinlin; Jiang, De-Ke*Journal of Clinical and Translational Hepatology, 2022, 11(2): 295-303.被引 3
- A Missense Variant in Granulysin is Associated with the Efficacy of Pegylated-Interferon-Alpha Therapy in Chinese Patients with HBeAg-Positive Chronic Hepatitis BLi, Jing; Chen, Haitao; Chen, Jiaxuan; Zhou, Bin; Hou, Jinlin*; Jiang, De-Ke*Pharmacogenomics and Personalized Medicine, 2021, 14: 1505-1515.被引 5
